US 12,240,816 B2
Deuterated compounds and uses thereof
Todd Brady, Carlisle, MA (US); Scott Young, E. Falmouth, MA (US); William A. Kinney, Newtown, PA (US); and Susan MacDonald, Danvers, MA (US)
Assigned to Aldeyra Therapeutics, Inc., Lexington, MA (US)
Filed by Aldeyra Therapeutics, Inc., Lexington, MA (US)
Filed on Nov. 8, 2023, as Appl. No. 18/504,672.
Application 18/504,672 is a continuation of application No. 17/929,505, filed on Sep. 2, 2022, granted, now 11,845,722.
Application 17/929,505 is a continuation of application No. 17/324,318, filed on May 19, 2021, granted, now 11,459,300, issued on Oct. 4, 2022.
Application 17/324,318 is a continuation of application No. 16/720,645, filed on Dec. 19, 2019, granted, now 11,046,650, issued on Jun. 29, 2021.
Application 16/720,645 is a continuation of application No. 15/754,065, granted, now 10,550,085, issued on Feb. 4, 2020, previously published as PCT/US2016/048054, filed on Aug. 22, 2016.
Claims priority of provisional application 62/208,223, filed on Aug. 21, 2015.
Prior Publication US 2024/0132451 A1, Apr. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 215/38 (2006.01); A61K 31/47 (2006.01); A61K 45/06 (2006.01); A61P 17/00 (2006.01); A61P 27/02 (2006.01); A61P 39/00 (2006.01)
CPC C07D 215/38 (2013.01) [A61K 31/47 (2013.01); A61K 45/06 (2013.01); A61P 17/00 (2018.01); A61P 27/02 (2018.01); A61P 39/00 (2018.01); C07B 2200/05 (2013.01)] 20 Claims
 
1. A compound of Formula II-B:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from —NH2, —NHD, or —ND2;
R2 is selected from hydrogen or deuterium;
R3 and R4 are independently selected from —CH3, —CH2D, —CHD2, or —CD3; and
R5, R6, R7, and R8 are each independently selected from hydrogen or deuterium.